Trial Profile

Phase 1b trial of ENV-294 in patients with moderate to severe atopic dermatitis.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ENV 294 (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

16 Sep 2025 According to Dr. Vince Clinical Research media release, the first patient has been dosed.
04 Sep 2025 According to Enveda media release, In Sep 2025, company raised US150 million dollars in an oversubscribed Series D funding and this funding will advance multiple clinical programs into phase Ib and phase II trials.
04 Sep 2025 Status changed to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com